RxDoctor Payments Data

Lauren Pingleton

Family · Stanford, KYNPI 1639500051

Payments from drug & device makers

$532in general payments, 2019–2025

Across 33 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$204
  • Vanda Pharmaceuticals Inc.$64
  • Lilly USA, LLC$52
  • Exact Sciences$46
  • Novo Nordisk$35
  • AstraZeneca$34
  • plus $96 from 5 others

What the payments were for

  • Food & beverage$532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$532 in reported general payments places this provider in the 50th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$506
Medicare patients
40
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide53$76,838
JardianceEmpagliflozin46$52,044
Tresiba Flextouch U-200Insulin Degludec21$36,354
JanuviaSitagliptin Phosphate22$17,103
EliquisApixaban18$15,279
LinzessLinaclotide12$14,380
Breo ElliptaFluticasone/Vilanterol22$12,798
Tresiba Flextouch U-100Insulin Degludec18$11,950
XareltoRivaroxaban13$10,552
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$5,596
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$2,975
Novolog FlexpenInsulin Aspart17$2,870
Varenicline Tartrate14$2,817
Potassium Chloride102$2,444
Albuterol Sulfate HfaAlbuterol Sulfate81$2,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$35$76,83853 claims
Boehringer IngelheimJardiance$17$52,04446 claims
AbbVieLinzess, Synthroid$204$14,99432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,374 family providers in Kentucky.

Other family in Stanford

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →